Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 10, 2026, 6:01 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Control Subjects Clear all
Completed Phase 2 Interventional

Study Evaluating SRA-333 in Mild to Moderate Alzheimer's Disease (AD)

NCT00151333
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
SRA-333
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
50 Years to 85 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
3
States / cities
Phoenix, Arizona • Fort Lauderdale, Florida • Miami, Florida
Source: ClinicalTrials.gov public record
Updated Sep 3, 2009 · Synced Jun 10, 2026, 6:01 AM EDT
Completed Phase 3 Interventional

A Study of Single-Dose Gabapentin in Subjects With Transient Insomnia Induced by a Sleep Phase Advance

NCT00666939
View directory record Official record
Conditions
Transient Insomnia
Interventions
Gabapentin, Placebo
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years and older
Enrollment
773 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
10
States / cities
San Diego, California • Ocala, Florida • Atlanta, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 1, 2021 · Synced Jun 10, 2026, 6:01 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

TC-6987 for the Treatment of Mild to Moderate Asthma

NCT01296087
View directory record Official record
Conditions
Asthma
Interventions
TC-6987, Placebo
Drug
Lead sponsor
Targacept Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
203 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
21
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 18 more
Source: ClinicalTrials.gov public record
Updated Sep 12, 2013 · Synced Jun 10, 2026, 6:01 AM EDT
Completed Phase 2 Interventional Results available

A Study to Assess Immunization Responses in Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis Treated With Nemolizumab

NCT04365387
View directory record Official record
Conditions
Dermatitis, Atopic
Interventions
Nemolizumab, Placebo
Drug
Lead sponsor
Galderma R&D
Industry
Eligibility
12 Years to 54 Years
Enrollment
242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
64
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Fort Smith, Arkansas + 53 more
Source: ClinicalTrials.gov public record
Updated May 31, 2026 · Synced Jun 10, 2026, 6:01 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Human Repeated Insult Patch Test (HRIPT) of Azelaic Acid Pre Foam Formulation

NCT01430533
View directory record Official record
Conditions
Healthy
Interventions
azelaic acid pre foam formulation, Vehicle pre foam formulation, Water
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
18 Years to 65 Years
Enrollment
240 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Mar 31, 2020 · Synced Jun 10, 2026, 6:01 AM EDT
Terminated Phase 3 Interventional Results available

Comparison of Fasiglifam (TAK-875) to Placebo and Sitagliptin in Combination With Metformin in Participants With Type 2 Diabetes

NCT01549964
View directory record Official record
Conditions
Glycemic Control
Interventions
Fasiglifam (TAK-875), Sitagliptin, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
916 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
58
States / cities
Muscle Shoals, Alabama • Mesa, Arizona • Peoria, Arizona + 55 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2016 · Synced Jun 10, 2026, 6:01 AM EDT
Completed Phase 3 Interventional Results available

Dexmedetomidine in the Treatment of Agitation Associated With Dementia (TRANQUILITY II)

NCT05271552
View directory record Official record
Conditions
Agitation, Dementia
Interventions
BXCL501, Matching Placebo
Drug
Lead sponsor
BioXcel Therapeutics Inc
Industry
Eligibility
65 Years and older
Enrollment
151 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
11
States / cities
Phoenix, Arizona • Long Beach, California • Daytona Beach, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Dec 30, 2025 · Synced Jun 10, 2026, 6:01 AM EDT
Completed Phase 3 Interventional Results available

An Efficacy and Safety Study of Extended-Release (ER) Paliperidone in Adolescent Participants With Schizophrenia

NCT01009047
View directory record Official record
Conditions
Schizophrenia
Interventions
Paliperidone extended release (ER), Aripiprazole
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
12 Years to 17 Years
Enrollment
228 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
6
States / cities
Dothan, Alabama • Santa Ana, California • Atlanta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 20, 2013 · Synced Jun 10, 2026, 6:01 AM EDT
Recruiting Phase 2 Interventional

Study With Phage for CF Subjects With Pseudomonas Lung Infection

NCT06998043
View directory record Official record
Conditions
Chronic Pseudomonas Aeruginosa Infection, Cystic Fibrosis (CF)
Interventions
BX004, Placebo
Biological · Other
Lead sponsor
BiomX Ltd
Industry
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
14
States / cities
Birmingham, Alabama • Anchorage, Alaska • Little Rock, Arkansas + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2025 · Synced Jun 10, 2026, 6:01 AM EDT
Completed Phase 2 Interventional Results available

Safety and Tolerability of Repeat Dosing of GSK233705/GW642444 in COPD

NCT00749411
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Placebo, GSK233705/GW642444
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
40 Years to 80 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
12
States / cities
Mobile, Alabama • Wheat Ridge, Colorado • Biddeford, Maine + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2020 · Synced Jun 10, 2026, 6:01 AM EDT
Completed Phase 2 Interventional Results available

A Comparison of Crotalinae Equine Immune F(ab)2 Antivenom (Anavip) and Crotalidae Polyvalent Immune Fab,

NCT00868309
View directory record Official record
Conditions
Snake Bite, Blood Coagulation Disorders
Interventions
Anavip, CroFab
Biological
Lead sponsor
Instituto Bioclon S.A. de C.V.
Industry
Eligibility
18 Years to 70 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 17, 2016 · Synced Jun 10, 2026, 6:01 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety in Subjects With Type 2 Diabetes Receiving Subcutaneous Basal Insulin and Prandial Inhalation of Technosphere/Insulin Versus Subcutaneous Premixed Insulin Therapy Over a 52-Week Treatment Period and a 4-Week Follow-up

NCT00309244
View directory record Official record
Conditions
Diabetes Type 2
Interventions
Technosphere® Insulin Inhalation Powder, 70% insulin aspart protamine suspension and 30% insulin aspart injection (rDNA origin)
Drug
Lead sponsor
Mannkind Corporation
Industry
Eligibility
18 Years to 80 Years
Enrollment
677 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
80
States / cities
Mobile, Alabama • Tucson, Arizona • Chula Vista, California + 54 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2014 · Synced Jun 10, 2026, 6:01 AM EDT
Terminated Phase 3 Interventional Results available

To Assess Safety/Efficacy of ELAD in Subjects w/ Severe Acute Alcoholic Hepatitis (sAAH) and Lille Score Failure

NCT01829347
View directory record Official record
Conditions
Severe Acute Alcoholic Hepatitis
Interventions
ELAD, Standard of Care treatment
Biological · Other
Lead sponsor
Vital Therapies, Inc.
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
21
States / cities
Little Rock, Arkansas • San Diego, California • Washington D.C., District of Columbia + 16 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2019 · Synced Jun 10, 2026, 6:01 AM EDT
Terminated Phase 2 Interventional Results available

NEXAGON for the Treatment of Corneal Persistent Epithelial Defects Following Severe Ocular Injuries

NCT04081103
View directory record Official record
Conditions
Corneal Persistent Epithelial Defect
Interventions
Nexagon® (lufepirsen) High Dose Concentration, Nexagon® (lufepirsen) Low Dose Concentration, Vehicle, Open-label Nexagon® (lufepirsen)
Drug
Lead sponsor
Glaukos Corporation
Industry
Eligibility
Not listed
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 13, 2025 · Synced Jun 10, 2026, 6:01 AM EDT
Completed Phase 2 Interventional Results available

A Phase 2 Double-masked Study of VVN539 in Subjects With Elevated Intraocular Pressure

NCT05451329
View directory record Official record
Conditions
Glaucoma, Open-Angle
Interventions
VVN539 Ophthalmic Solution 0.02%, VVN539 Ophthalmic Solution 0.04%, VVN539 Ophthalmic Solution Vehicle
Drug
Lead sponsor
VivaVision Biotech, Inc
Industry
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 16, 2024 · Synced Jun 10, 2026, 6:01 AM EDT
Completed Phase 3 Interventional Results available

Phase 3 Study of Hydrocodone Bitartrate Controlled-release Capsules in Subjects With Chronic Low Back Pain

NCT01081912
View directory record Official record
Conditions
Back Pain Lower Back Chronic
Interventions
Placebo, Hydrocodone bitartrate
Drug
Lead sponsor
Zogenix, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
510 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
51
States / cities
Phoenix, Arizona • Jonesboro, Arkansas • Anaheim, California + 47 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2022 · Synced Jun 10, 2026, 6:01 AM EDT
Terminated Phase 3 Interventional

Efficacy, Safety and Tolerability of Pioglitazone-Azilsartan in Subjects With Type 2 Diabetes Mellitus

NCT00376181
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Pioglitazone and Azilsartan, Pioglitazone
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
59
States / cities
Huntsville, Alabama • Tallassee, Alabama • Little Rock, Arkansas + 56 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2010 · Synced Jun 10, 2026, 6:01 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

A Study to Assess the Pharmacodynamic Interaction Between Gabapentin and Ethanol in Healthy Subjects

NCT00666796
View directory record Official record
Conditions
Insomnia
Interventions
Placebo ethanol, Ethanol, Placebo, Gabapentin
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
21 Years to 50 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 1, 2021 · Synced Jun 10, 2026, 6:01 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Lybridos in Pre-and Postmenopausal Women With Hypoactive Sexual Desire Disorder

NCT02101203
View directory record Official record
Conditions
Hypoactive Sexual Desire Disorder
Interventions
Placebo, 0.5 mgTestosterone + 10 mg Buspirone
Drug
Lead sponsor
Emotional Brain NY Inc.
Industry
Eligibility
21 Years to 70 Years · Female only
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
10
States / cities
San Diego, California • Bradenton, Florida • Orlando, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2015 · Synced Jun 10, 2026, 6:01 AM EDT
Completed Phase 3 Interventional Results available

Safety Study of the Potential Inhibitory Effects of Ciclesonide Nasal Aerosol on the Hypothalamic-Pituitary-Adrenal Axis in Subjects 6-11 Years With Perennial Allergic Rhinitis

NCT01378429
View directory record Official record
Conditions
Perennial Allergic Rhinitis, PAR
Interventions
ciclesonide nasal aerosol, Placebo
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
6 Years to 11 Years
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
7
States / cities
Costa Mesa, California • Stockbridge, Georgia • Normal, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated May 25, 2014 · Synced Jun 10, 2026, 6:01 AM EDT
Completed Phase 2 Interventional Results available

Use of Infliximab for the Treatment of Pemphigus Vulgaris

NCT00283712
View directory record Official record
Conditions
Pemphigus
Interventions
Infliximab, Placebo Comparator
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
4
States / cities
Los Angeles, California • Iowa City, Iowa • Durham, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 5, 2017 · Synced Jun 10, 2026, 6:01 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of SY-201 Ophthalmic Solution in Subjects With Dry Eye Disease

NCT05370495
View directory record Official record
Conditions
Dry Eye Disease
Interventions
SY-201 Ophthalmic Solution 2.0%, SY-201 Ophthalmic Solution 1.0%, SY-201 Ophthalmic Solution 0.5%, SY-201 Ophthalmic Solution Vehicle
Drug
Lead sponsor
Seinda Pharmaceutical Guangzhou Corporation
Industry
Eligibility
18 Years to 99 Years
Enrollment
201 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 25, 2024 · Synced Jun 10, 2026, 6:01 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Repeat Dose Pharmacokinetic (PK) and Safety Study of GSK2838232 With and Without Ritonavir (RTV) Conducted in Healthy Subjects

NCT02289495
View directory record Official record
Conditions
Infection, Human Immunodeficiency Virus
Interventions
GSK2838232, Placebo, Ritonavir
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 8, 2017 · Synced Jun 10, 2026, 6:01 AM EDT
Completed Phase 2 Interventional

Efficacy and Safety of Ramelteon in Subjects With Mild to Moderate Alzheimer's Disease

NCT00325728
View directory record Official record
Conditions
Chronic Insomnia
Interventions
Ramelteon, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
55 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
72
States / cities
Alabaster, Alabama • Huntsville, Alabama • Phoenix, Arizona + 69 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2017 · Synced Jun 10, 2026, 6:01 AM EDT